Suros Surgical Systems Inc.
This article was originally published in Start Up
Executive Summary
J&J Subsidiary Biopsys pioneered minimally-invasive breast core biopsy and was the lone player in the market for years. But now, Suros Surgical Systems has launched a competing vacuum-assisted biopsys system that is making incursions on J&J's market share with an improved technology that is the first that is suitable for MRI-guided breast biopsy.
You may also be interested in...
Breast Biopsy Devices: Interventional Medicine Comes to Breast Cancer
In breast cancer, the need for less invasive alternatives to surgery is gaping, particularly on the diagnostic side. Following routine screening mammography, 1.4 million women in the US each year have breast biopsies once a radiologist identifies a suspicious lesion. However, only 20% of women undergoing biopsies will be found to have cancer and not just abnormal, but benign growths. Several new companies have gone to the drawing board to remedy the shortcomings of biopsy devices.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.